- Ono Pharma has reduced its forecast for fiscal year operating income from an initially expected 82.00 billion yen to 60.00 billion yen. The market estimated the figure to be 91.12 billion yen.
- The company anticipates a net income of 50.00 billion yen, down from the previously projected 58.00 billion yen. This figure falls short of the market’s estimate of 66.65 billion yen.
- Net sales are now expected to be 487.00 billion yen, slightly higher than the previous figure of 485.00 billion yen but lower than the market’s estimate of 493.75 billion yen.
- Analyst ratings on Ono Pharma include 3 buy recommendations, 6 hold recommendations, and 5 sell recommendations.
- All comparisons are based on figures previously disclosed by Ono Pharma in their original reports.
Ono Pharmaceutical on Smartkarma
On Smartkarma, analyst Tina Banerjee‘s coverage of Ono Pharmaceutical (4528 JP) paints a challenging outlook for the company. In a recent report titled “Ono Pharmaceutical (4528 JP): Struggle Continues with Opdivo; Competition and Price Cuts Loom Large,” Banerjee highlights the slowdown in revenue from Ono’s flagship drug, Opdivo. With a 17% YoY decrease in domestic revenue during H1FY25 and the looming patent cliff in 2028, Ono Pharmaceutical faces significant headwinds. The company’s shares have declined by 36% in the past year, reflecting limited growth prospects and a need for new drug commercialization to navigate the patent cliff successfully.
Analyst sentiment leans bearish as Banerjee underscores the challenges ahead for Ono Pharmaceutical. The report points out the necessity for prolific commercialization of new drugs to offset the revenue decline from Opdivo. Despite trading at an attractive valuation due to the share price drop, Ono’s stock may not experience significant upside in the absence of near-term growth catalysts. Investors following the analyst coverage on Smartkarma are advised to monitor how Ono Pharmaceutical addresses the competitive pressures and patent cliff to assess the company’s long-term prospects.
A look at Ono Pharmaceutical Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 5 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 4.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Ono Pharmaceutical, a leading pharmaceutical company known for its research and development of prescription drugs, has garnered positive scores across key factors according to Smartkarma Smart Scores. With a strong emphasis on shareholder returns, Ono Pharmaceutical boasts a top score of 5 in Dividend, indicating a robust commitment to rewarding its investors. Additionally, the company has received high scores in other critical areas such as Value (4), Resilience (4), and Momentum (4), reflecting a well-rounded performance across different aspects of its operations.
Looking ahead, Ono Pharmaceutical‘s favorable Smart Scores paint a promising long-term outlook for the company. The high scores in Dividend, Value, Resilience, and Momentum suggest a solid foundation and growth potential in the pharmaceutical sector. While Growth scored slightly lower at 3, the overall positive assessment indicates that Ono Pharmaceutical is well-positioned to thrive in the competitive market landscape, offering investors a potentially attractive opportunity in the healthcare industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
